Accelerating Rare Disease Treatments: New Rules for Orphan Drugs
This act aims to streamline the approval process for drugs treating rare diseases, known as orphan drugs. It introduces new reporting and study requirements to ensure patients gain faster access to necessary therapies. It also increases the involvement of experts and patients in the drug evaluation process.
Key points
Annual Reports on Orphan Drugs: The Food and Drug Administration (FDA) will annually publish detailed reports on rare disease drugs, including the number of applications submitted and approved. This information will be publicly available.
Study of European Practices: A study will be conducted on how the European Union evaluates rare disease drugs to identify ways to improve similar processes in the U.S.
Increased Expert and Patient Involvement: Experts in rare diseases will be required to participate in the evaluation process for rare disease drugs. Additionally, when establishing drug safety rules, the FDA will consult with patients to ensure these rules are feasible for them.
Expired
Citizen Poll